TickerTalks
Browse all tickers →
TickerTalks›$OPK
OPOPK

OPKO Health, Inc.

$OPK·$1.0B·Medical - Diagnostics & Research·Healthcare
$1.53-5.0%YTD+4.8%1Y+2.0%
Price updated 7h ago·X counts updated 5d ago
OPOPK
$OPKOPKO Health, Inc.
$1.53-4.97%3 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $OPK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

3X posts · last 7 days
Sep 29Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $OPK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Comeback attemptEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

OPKO Health pivots to therapeutics with 12-18 months of data-rich catalysts — Nov 4 earnings tests the pivot thesis.

OPKO Health is a diversified healthcare company whose 2026 pivot is specific — the strategic shift to therapeutics with 12-18 months of 'data-rich' catalysts is the explicit management framework.

  • The P&L is uneven but surprising-even: Q2 revenue grew 4.3% YoY to $164M at a -4.3% operating margin and EPS of -$0.01, with trailing EPS beats of 87.5% and 0% — these are small-dollar surprises typical of a diversified healthcare company whose therapeutics-pivot is in early stages.
  • The specific capital-markets positioning is substantive: 'OPK Stock Climbs 32.5% YTD' coverage plus 'OPKO Health Pivots to Therapeutics' sector-framing — these are coordinated signals that specialist capital is positioning around the pivot execution.

At 75% of its 52-week range going into Nov 4 earnings, the setup is positioned for continuation. A clean therapeutics-pipeline progression commentary plus continued operating-margin direction is the trigger for a reclaim; a soft BioReference Health segment or any specific Rayaldee commercial signal is the invalidation.

What to watch: Nov 4 Q3 earnings — therapeutics-pipeline progression, BioReference Health segment, operating margin direction, and FY27 guide. Pipeline-advancement plus margin direction is the trigger; segment softness is the invalidation.

On the calendar: 2026-11-04 — Q3 earnings

event ahead 30dtherapeutics pivot

Read the AI verdict on $OPK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Diagnostics and specialty pharma company with US lab services, growth hormone therapy, and international operations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $OPK.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $OPK

Partial — Diagnostics and specialty pharma company with US lab services, growth hormone therapy, and international operations.

Industry benchmark

19-name peer basket
+38.3%YTD
+45.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-17.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-25.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-5.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
42.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 27, 2026$-0.01$-0.08+87.5%
Q1 2026Apr 28, 2026$-0.07$-0.070.0%
Q4 2025Feb 26, 2026$-0.04$-0.07+42.9%
Q3 2025Oct 29, 2025$0.03$-0.02+250.0%
Next earningsWed, Nov 4·consensus EPS $-0.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$163.6M+4.3%48.9%-4.3%$-0.01$-46.5M
Q1 FY26$124.2M-17.2%21.6%-41.1%$-0.07$-21.1M
Q4 FY25$148.4M-19.2%30.3%-25.8%$-0.04$-28.6M
Q3 FY25$151.7M-12.6%20.0%-35.3%$0.03$-37.8M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$569.9M$567.3M – $573.7M-$0.22-$0.24 – -$0.195
FY27$589.0M$575.9M – $601.9M-$0.27-$0.29 – -$0.225
FY28$605.8M$602.8M – $608.8M-$0.24-$0.28 – -$0.212
FY29$651.4M$641.4M – $665.6M-$0.20-$0.21 – -$0.201
FY30$700.2M$689.4M – $715.4M-$0.19-$0.20 – -$0.191

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.70%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 323.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (6 awards · 2 inkinds) in window

See when $OPK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementOct 158-K — Item 1.01: Material agreement
8-KMaterial agreementAug 148-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

OPKO Health, Inc. issued $125 million in additional senior secured notes on August 13, 2026 via an amendment to its July 2024 Note Purchase Agreement with HCR Injection SPV, LLC as agent. The notes mature July 17, 2044, bear interest at 3-month SOFR + 7.5% per annum (4.0% floor), with quarterly interest paid from EirGen Pharma's Pfizer profit-share royalties; they are secured by EirGen's royalty interest in mazdutide (Eli Lilly-licensed) and capped at $187.5M in Mazdutide repayments. This royalty-monetization financing ties OPKO's debt repayment directly to mazdutide's commercial traction in China, a material and long-dated obligation.

SC 13DActivist position (5%+)Aug 7SC 13D
AI summary

FROST PHILLIP MD ET AL 2 Check the appropriate box if a membe filed a new Schedule 13D disclosing a beneficial ownership position of 13.9% in OPK (OPK) as of 2026-08-07. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

SC 13D/AActivist amendmentJul 1SC 13D/A
AI summary

FROST PHILLIP MD ET AL filed an amended Schedule 13D for Common Stock, par value $0.01 per share (OPK) beneficially owning 255,429,406 shares. Reported for potential strategic or activist purposes. SC 13D is required when a beneficial owner crosses 5% with active intent. This amendment updates a prior position. Watch for follow-on disclosures about board engagement, deals, or governance proposals.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

OPKO Health, Inc (OPK) reported stockholder vote results (Item 5.07, filed 2026-06-18). Votes covered: director elections, equity plan. Proposals approved by shareholders. Annual votes cover routine governance; material proposals (equity plan expansions) warrant closer review. Check tallies for contested or close votes.

+ 11 other (4 10-Qs · 3 proxys · 2 earnings 8-Ks · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

OPKO Health to Sell Select BioReference Assets to Labcorp for $722Mzacks.com·15h agoOPKO Health Sheds Diagnostics Businesses in Major Labcorp Dealbenzinga.com·2d agoLabcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Healthprnewswire.com·2d agoComparing Ardent Health (NYSE:ARDT) & OPKO Health (NASDAQ:OPK)defenseworld.net·10d agoOPKO Health, Inc. (NASDAQ:OPK) Stock Now Rated “Hold” by Sell-Side Analystsdefenseworld.net·14d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$ILMN$TMO$GH$NTRA$DHR$GRAL
Voices on X · last 7 days

No standout posts about $OPK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport